Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025
1. Nektar announces REZOLVE-AD Phase 2b results presentation at EADV Congress 2025. 2. Presentation includes efficacy data from patients treated with rezpegaldesleukin. 3. FDA granted Fast Track designation for rezpegaldesleukin for atopic dermatitis. 4. Rezpegaldesleukin aims to treat autoimmune diseases by regulating T cells. 5. The study involves 110 global sites; primarily in Europe.